Platinum‐based chemotherapy plus cetuximab first‐line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of …
Y Guo, M Shi, A Yang, J Feng, X Zhu, YJ Choi… - Head & …, 2015 - Wiley Online Library
Background The purpose of this study was to assess the efficacy, safety, and
pharmacokinetics of cisplatin‐based chemotherapy plus cetuximab as first‐line treatment in …
pharmacokinetics of cisplatin‐based chemotherapy plus cetuximab as first‐line treatment in …
Multicenter phase II study of cetuximab plus docetaxel in 84 patients with recurrent or metastatic, platinum-pretreated SCCHN
MK Knoedler, T Gauler, A Matzdorff… - Journal of Clinical …, 2009 - ascopubs.org
6048 Background: Cetuximab and docetaxel are both active in squamous cell carcinoma of
the head and neck (SCCHN). We investigated the efficacy of cetuximab plus docetaxel as …
the head and neck (SCCHN). We investigated the efficacy of cetuximab plus docetaxel as …
Cetuximab in the treatment of squamous cell carcinoma of the head and neck
P Specenier, JB Vermorken - Expert review of anticancer therapy, 2011 - Taylor & Francis
The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer
Cetuximab is typically administered on a weekly schedule for patients with recurrent or
metastatic head and neck squamous cell cancer (HNSCC). This study explores cetuximab …
metastatic head and neck squamous cell cancer (HNSCC). This study explores cetuximab …
Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Indian tertiary care retrospective analysis
A Bahl, K Bhatia, P Choudhary, S Singhla… - Head & …, 2020 - Wiley Online Library
Background We report our experience with Indian patients who received palliative
chemotherapy with/without cetuximab for recurrent/metastatic squamous cell carcinoma of …
chemotherapy with/without cetuximab for recurrent/metastatic squamous cell carcinoma of …
[HTML][HTML] Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study
S Tiwari, V Goel, MC John, N Patnaik… - Indian Journal of …, 2016 - journals.lww.com
BACKGROUND: In squamous cell carcinoma of the head and neck (SCCHN), epidermal
growth factor receptor is expressed at very high levels. Hence, we have done this study to …
growth factor receptor is expressed at very high levels. Hence, we have done this study to …
[HTML][HTML] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell …
R Hitt, A Irigoyen, H Cortes-Funes, JJ Grau… - Annals of …, 2012 - Elsevier
Background The efficacy and safety of a novel combination of weekly paclitaxel and the
epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line …
epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line …
[HTML][HTML] Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab …
D Soulieres, JL Aguilar, E Chen, K Misiukiewicz… - BMC cancer, 2016 - Springer
Background Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck
R Mehra, RB Cohen, PM Harari - Current oncology reports, 2008 - Springer
Squamous cell carcinoma of the head and neck (SCCHN) continues to be a source of
significant morbidity and mortality. Agents that target the epidermal growth factor receptor …
significant morbidity and mortality. Agents that target the epidermal growth factor receptor …
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck …
J Guigay, A Aupérin, J Fayette, E Saada-Bouzid… - The Lancet …, 2021 - thelancet.com
Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–
platinum–cetuximab) showed promising results, with a median overall survival of 14· 0 …
platinum–cetuximab) showed promising results, with a median overall survival of 14· 0 …